Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
14
HCM Quote, Financials, Valuation and Earnings
Last price:
$13.48
Seasonality move
:
-5.04%
Day range:
$13.22 - $13.56
52-week range:
$11.51 - $19.50
Dividend yield:
0%
P/E ratio:
5.04x
P/S ratio:
3.91x
P/B ratio:
2.36x
Volume:
11.9K
Avg. volume:
27.2K
1-year change:
-5.45%
Market cap:
$2.3B
Revenue:
$630.5M
EPS (TTM):
$2.66
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $22.58 |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$26M | -- | 265.18% | -- | $26.00 |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
$13.52 | $22.58 | $2.3B | 5.04x | $0.00 | 0% | 3.91x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
$0.75 | -- | $8.2M | 8.18x | $0.00 | 0% | 0.75x |
|
PRE
Prenetics Global Ltd.
|
$16.91 | $26.00 | $284.6M | -- | $0.00 | 0% | 3.29x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
$24.60 | -- | $12.2B | -- | $0.00 | 0% | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
$18.22 | -- | $16.3B | 31.84x | $0.13 | 1.26% | 3.87x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.509 | -- | 4.41x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | 0.000 | -- | -- |
|
PRE
Prenetics Global Ltd.
|
1.29% | 4.220 | 1.18% | 1.01x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 21.200 | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
23.1% | -0.180 | -- | 1.14x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$14M | -$6.6M | -26.04% | -26.74% | -27.85% | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | 6.83% | 8.57% | -- | -- |
HUTCHMED (China) Ltd. vs. Competitors
-
Which has Higher Returns HCM or HKPD?
Hong Kong Pharma Digital Technology Holdings Ltd. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of --. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat Hong Kong Pharma Digital Technology Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B HKPDHong Kong Pharma Digital Technology Holdings Ltd.-- -- -- -
What do Analysts Say About HCM or HKPD?
HUTCHMED (China) Ltd. has a consensus price target of $22.58, signalling upside risk potential of 67.05%. On the other hand Hong Kong Pharma Digital Technology Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) Ltd. has higher upside potential than Hong Kong Pharma Digital Technology Holdings Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Hong Kong Pharma Digital Technology Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 HKPDHong Kong Pharma Digital Technology Holdings Ltd.0 0 0 -
Is HCM or HKPD More Risky?
HUTCHMED (China) Ltd. has a beta of 0.416, which suggesting that the stock is 58.402% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HCM or HKPD?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hong Kong Pharma Digital Technology Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCM or HKPD?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings Ltd. quarterly revenues of --. HUTCHMED (China) Ltd.'s net income of -- is lower than Hong Kong Pharma Digital Technology Holdings Ltd.'s net income of --. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 5.04x while Hong Kong Pharma Digital Technology Holdings Ltd.'s PE ratio is 8.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 3.91x versus 0.75x for Hong Kong Pharma Digital Technology Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.3.91x 5.04x -- -- HKPDHong Kong Pharma Digital Technology Holdings Ltd.0.75x 8.18x -- --
-
Which has Higher Returns HCM or PRE?
Prenetics Global Ltd. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of -28.82%. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat Prenetics Global Ltd.'s return on equity of -26.74%.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B PREPrenetics Global Ltd.59.54% -$0.53 $163.3M -
What do Analysts Say About HCM or PRE?
HUTCHMED (China) Ltd. has a consensus price target of $22.58, signalling upside risk potential of 67.05%. On the other hand Prenetics Global Ltd. has an analysts' consensus of $26.00 which suggests that it could grow by 83.32%. Given that Prenetics Global Ltd. has higher upside potential than HUTCHMED (China) Ltd., analysts believe Prenetics Global Ltd. is more attractive than HUTCHMED (China) Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 PREPrenetics Global Ltd.1 0 0 -
Is HCM or PRE More Risky?
HUTCHMED (China) Ltd. has a beta of 0.416, which suggesting that the stock is 58.402% less volatile than S&P 500. In comparison Prenetics Global Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HCM or PRE?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. Prenetics Global Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCM or PRE?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than Prenetics Global Ltd. quarterly revenues of $23.6M. HUTCHMED (China) Ltd.'s net income of -- is lower than Prenetics Global Ltd.'s net income of -$6.8M. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 5.04x while Prenetics Global Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 3.91x versus 3.29x for Prenetics Global Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.3.91x 5.04x -- -- PREPrenetics Global Ltd.3.29x -- $23.6M -$6.8M
-
Which has Higher Returns HCM or RGC?
Regencell Bioscience Holdings Ltd. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of --. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat Regencell Bioscience Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B RGCRegencell Bioscience Holdings Ltd.-- -- -- -
What do Analysts Say About HCM or RGC?
HUTCHMED (China) Ltd. has a consensus price target of $22.58, signalling upside risk potential of 67.05%. On the other hand Regencell Bioscience Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 RGCRegencell Bioscience Holdings Ltd.0 0 0 -
Is HCM or RGC More Risky?
HUTCHMED (China) Ltd. has a beta of 0.416, which suggesting that the stock is 58.402% less volatile than S&P 500. In comparison Regencell Bioscience Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HCM or RGC?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. Regencell Bioscience Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCM or RGC?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than Regencell Bioscience Holdings Ltd. quarterly revenues of --. HUTCHMED (China) Ltd.'s net income of -- is lower than Regencell Bioscience Holdings Ltd.'s net income of --. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 5.04x while Regencell Bioscience Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 3.91x versus -- for Regencell Bioscience Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.3.91x 5.04x -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- --
-
Which has Higher Returns HCM or SBHMY?
Sino Biopharmaceutical Ltd. has a net margin of -- compared to HUTCHMED (China) Ltd.'s net margin of --. HUTCHMED (China) Ltd.'s return on equity of 50.64% beat Sino Biopharmaceutical Ltd.'s return on equity of 8.57%.
Company Gross Margin Earnings Per Share Invested Capital HCMHUTCHMED (China) Ltd.-- -- $1.3B SBHMYSino Biopharmaceutical Ltd.-- -- $7.2B -
What do Analysts Say About HCM or SBHMY?
HUTCHMED (China) Ltd. has a consensus price target of $22.58, signalling upside risk potential of 67.05%. On the other hand Sino Biopharmaceutical Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HCMHUTCHMED (China) Ltd.9 2 1 SBHMYSino Biopharmaceutical Ltd.0 0 0 -
Is HCM or SBHMY More Risky?
HUTCHMED (China) Ltd. has a beta of 0.416, which suggesting that the stock is 58.402% less volatile than S&P 500. In comparison Sino Biopharmaceutical Ltd. has a beta of 0.555, suggesting its less volatile than the S&P 500 by 44.514%.
-
Which is a Better Dividend Stock HCM or SBHMY?
HUTCHMED (China) Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical Ltd. offers a yield of 1.26% to investors and pays a quarterly dividend of $0.13 per share. HUTCHMED (China) Ltd. pays -- of its earnings as a dividend. Sino Biopharmaceutical Ltd. pays out 55.99% of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HCM or SBHMY?
HUTCHMED (China) Ltd. quarterly revenues are --, which are smaller than Sino Biopharmaceutical Ltd. quarterly revenues of --. HUTCHMED (China) Ltd.'s net income of -- is lower than Sino Biopharmaceutical Ltd.'s net income of --. Notably, HUTCHMED (China) Ltd.'s price-to-earnings ratio is 5.04x while Sino Biopharmaceutical Ltd.'s PE ratio is 31.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) Ltd. is 3.91x versus 3.87x for Sino Biopharmaceutical Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCMHUTCHMED (China) Ltd.3.91x 5.04x -- -- SBHMYSino Biopharmaceutical Ltd.3.87x 31.84x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
